Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Capecitabine; Cisplatin; Gemcitabine; Oxaliplatin; Pemetrexed
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Gastrointestinal cancer; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Cinda Biopharmaceutical; Innovent Biologics

    • Most Recent Events

    • 20 Sep 2022 Status changed from active, no longer recruiting to completed.
    • 05 Aug 2022 Results assessing safety and efficacy of sintilimab, anti-PD-1 monoclonal antibody, in treating advanced NENs published in the Oncologist
    • 01 Dec 2021 Results assessing PD-L1 Expression on circulating tumor cells for predicting clinical outcomes by using data from six clinical trials including this study published in the Oncologist

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top